Answers are grounded in this paper and cite their sources.
Randomized trial compares treatment efficacy of 11 targets in adults with metabolic dysfunction-associated liver disease, indicating safety and effectiveness.
Randomized controlled trials (RCTs) have been conducted to evaluate treatment efficacy for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis. This study aimed to compare the effectiveness and safety of 11 promising targets among adults with MASLD.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: